New drug CUE-102 targets recurrent brain cancer in early trial
Disease control
Recruiting now
This early-phase study tests an experimental drug called CUE-102 in 18 adults whose glioblastoma (a type of brain cancer) has come back after initial treatment. The main goal is to find the safest dose and check for side effects. Participants must have a specific genetic marker (…
Phase: PHASE1 • Sponsor: David Reardon, MD • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC